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Down Syndrome: Changing Cardiac Phenotype?
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Down syndrome (DS) is the most common chromosomal abnormality, affecting 1 in 700 
infants born yearly in the United States.1 The birth prevalence of DS varies internationally 
among populations, likely due to variations in maternal age, race/ethnicity, use of prenatal 
screening, and terminations of affected pregnancies.2, 3 Approximately half of all infants 
born with DS also have a congenital heart defect (CHD), the most common type being 
atrioventricular septal defect (AVSD), with rates from 30% to 60%.4 In the era of increasing 
maternal age and pregnancy terminations, 2 it is interesting to investigate if and how the 
pattern of associated CHDs among infants with DS has changed.
In this issue of Pediatrics, Bergstrom et al5 describe the pattern of CHDs among Swedish 
liveborn infants with DS from 1992 to 2012. In this nationwide, population-based cohort, 
over half had a CHD; the 3 most common being AVSD, ventricular septal defect, and atrial 
septal defect. Although the overall rate and risk for CHDs remained constant, differences 
were noted among CHD phenotypes over time. When adjusting for several factors, the risk 
of complex CHDs decreased by 40% from birth period 1992–1994 to birth period 2010–
2012, with a concurrent rise in less severe CHDs. Among livebirths with DS and CHDs, the 
rate of AVSD decreased from 46% to 30%, whereas the rate of ventricular septal defect 
doubled from 14% to 31%. The authors hypothesize this phenotypic shift could be the result 
of improved prenatal detection, especially among older mothers, leading to increased 
pregnancy termination.5
The finding of a phenotypic shift to less complex CHDs is intriguing but should be 
interpreted cautiously. First, although this is a large population-based study of DS livebirths, 
it lacked information on prenatal screening or pregnancy terminations. Understanding the 
true occurrence of CHDs would include not only livebirths, but also stillbirths and 
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: site/misc/
Permissions.xhtml
Address correspondence to Tiffany Riehle-Colarusso, MD, MPH, Centers for Disease Control and Prevention, 4770 Buford Highway, 
Mailstop E-86, Atlanta, GA 30341. tcolarusso@cdc.gov. 
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
Opinions expressed in these commentaries are those of the author and not necessarily those of the American Academy of Pediatrics or 
its Committees.
Financial Disclosure: The authors have indicated they have no financial relationships relevant to this article to disclose.
Potential Conflict of Interest: The authors have indicated they have no potential conflicts of interest to disclose.
Companion Paper: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2016-0123.
HHS Public Access
Author manuscript
Pediatrics. Author manuscript; available in PMC 2017 June 23.
Published in final edited form as:













terminations of pregnancy. Thus, it is unclear whether the decreased rate of AVSD among 
livebirths was due to increased pregnancy terminations or a change in the true occurrence of 
CHDs in all fetuses with DS. However, a French study by Stoll et al4 of all outcomes from 
DS-affected pregnancies over 26 years revealed a similar distribution of AVSD (30%) 
among those with CHDs, but did not investigate changes over time.4
Second, differences in underlying prevalence of both DS and CHDs across populations 
might limit the generalizability of the current findings. Documented prevalence variability is 
likely due to differences in study design, population characteristics (eg, maternal age or race/
ethnicity), time period, availability of prenatal care, and pregnancy terminations. For 
example, in the United States, racial/ethnic differences in prevalence and survival of children 
with DS, CHDs, or both have been observed, likely due to a multifactorial interaction as yet 
to be elucidated.3, 6–8 In Cocchi et al, 2 the stable birth prevalence of DS despite an increase 
in older mothers was attributed to the increased use of prenatal diagnoses and pregnancy 
terminations. Similarly, in this Pediatrics study, Bergstrom et al5 hypothesized that a 1% 
decreased risk of a CHD for every year of maternal age might be associated with more 
careful prenatal assessment and pregnancy termination. Although the percentage of DS 
births to older mothers was reported to be increasing internationally, the increase was much 
smaller in North American countries compared with Europe.2 A lower and more stable rate 
of pregnancy terminations in North America was also reported.2 Access to prenatal health 
care in the United States differs from Sweden, thereby potentially affecting the prenatal 
detection of CHDs and pregnancy terminations in the United States. Together these country-
specific differences could mean that a shift in cardiac phenotype among DS livebirths may 
not be as evident in the United States as in Sweden.
Although the survival of children born with DS and CHDs has greatly improved, these 
children are still at higher risk for mortality, 7 health care cost, 6 and neurodevelopmental 
delay9 compared with children born without birth defects. For example, in guidelines to 
optimize neurodevelopmental outcome for children with CHDs, children with DS and CHDs 
are at high-risk for developmental delay.9 If there is a decreasing trend in complex CHDs, 
then perhaps children with DS and CHDs might have better outcomes than previous 
generations. Understanding the phenotypic expression of DS is helpful for resource planning 
and targeting health care needs. Health supervision guidelines used by pediatricians who 
care for children with DS note that early intervention may improve outcomes and 
functioning.10
CHDs are 1 of the most serious conditions associated with DS, but there are other 
comorbidities. More research is needed to evaluate whether other common conditions such 
as hearing loss, obstructive sleep apnea, eye disease, cancer, or autoimmune diseases have 
changed in persons with DS, which could signal an improvement in overall health outcomes 
for this population.
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AVSD atrioventricular septal defect
CHD congenital heart defect
DS Down syndrome
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